Skip to main content
. 2019 Apr 1;10(2):278–292. doi: 10.14336/AD.2018.0917

Figure 2.

Figure 2.

Relative gene and protein expression levels of COL19A1 in the muscle biopsy study cohort. Gene and protein expression levels of COL19A1 in healthy subjects, ALS patients and other neuropathies patients (A). Kruskal Wallis tests showed significant differences among ALS patients and the other two groups under study, when gene and protein expression levels were tested (P < 0.001, **). (B) Areas under ROC curves (AUC) of gene and protein expression of COL19A1 were calculated to test its support for diagnosis criterion in ALS patients (P <0.001, **). A total of 49 ALS (FALS and SALS) participants were included in this study and matched with 24 control individuals, and 14 ONP; SE: standard error.